Adam P Yan, Yuqing Feng, Dima El Hassanieh, Allison Starr, Martin Yi, Tal Schechter-Finkelstein, Jennifer Drynan, Lillian Sung, Sumit Gupta
{"title":"尼塞维单抗预防免疫功能低下儿童癌症和干细胞移植受者的呼吸道合胞病毒感染：单中心经验","authors":"Adam P Yan, Yuqing Feng, Dima El Hassanieh, Allison Starr, Martin Yi, Tal Schechter-Finkelstein, Jennifer Drynan, Lillian Sung, Sumit Gupta","doi":"10.1002/pbc.32032","DOIUrl":null,"url":null,"abstract":"<p><p>Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long-acting monoclonal antibody approved in 2023, offers single-dose seasonal protection. We conducted a single-center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024-2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non-recipients, including one RSV-related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e32032"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single-Center Experience.\",\"authors\":\"Adam P Yan, Yuqing Feng, Dima El Hassanieh, Allison Starr, Martin Yi, Tal Schechter-Finkelstein, Jennifer Drynan, Lillian Sung, Sumit Gupta\",\"doi\":\"10.1002/pbc.32032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long-acting monoclonal antibody approved in 2023, offers single-dose seasonal protection. We conducted a single-center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024-2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non-recipients, including one RSV-related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.</p>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\" \",\"pages\":\"e32032\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pbc.32032\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.32032","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single-Center Experience.
Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long-acting monoclonal antibody approved in 2023, offers single-dose seasonal protection. We conducted a single-center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024-2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non-recipients, including one RSV-related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.
期刊介绍：
Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
